In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...

Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya ...

Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand ...

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...

Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...

Korro Bio is laying off a fifth of its workforce as the Novo Nordisk-partnered biotech funnels resources to its ...

Novo Nordisk (NVO) stock rises after Q1 2025 results, even after the company cut its outlook as it sees a sales recovery for ...